Tags : Just – Evotec Biologics

MSD Signs a Multiyear Agreement with Just – Evotec Biologics

Shots: Just-Evotec to receive $15M up front, milestones on completion of the construction of the J.POD facility (facility of the future) as well as a broad collaboration around reserved capacities Just – Evotec Biologics granted MSD access to manufacturing capacity in the J.POD facility in Redmond, Washington, which was co-developed by MSD and Just Biotherapeutics […]Read More

Insights+ Key Biosimilars Events of October 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the […]Read More

Biocon Biologics Signs an In-License Agreement with Just – Evotec

Shots: Biocon Biologics will perform all end-to-end development activities, IND filing, manufacturing and commercialization post-regulatory approval in its own authorized global markets for assets and will utilize Just – Evotec Biologics’ expertise in process development domain mainly in optimized manufacturability Just – Evotec Biologics to receive license fee plus development, regulatory and commercial milestone payments. […]Read More